Published in final edited form as:

J Allergy Clin Immunol. 2010 April ; 125(4): 946–949.e6. doi:10.1016/j.jaci.2009.12.983.

Using biomarkers to predict the presence of *FAS* mutations in patients with features of the autoimmune lymphoproliferative syndrome

Iusta Caminha, MD^a, Thomas A. Fleisher, MD^a, Ronald L. Hornung, PhD^e, Janet K. Dale, RN, MPH^b, Julie E. Niemela, MLS (ASCP)^a, Susan Price, RN^c, Joie Davis, CRNP^c, Katie Perkins, CRNP^f, Kennichi C. Dowdell, PhD^d, Margaret R. Brown, MLS (ASCP)^a, V. Koneti Rao, MD^c, and João Bosco Oliveira, MD, PhD^a

João Bosco Oliveira: oliveirajb@cc.nih.gov

^aDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Md

^bOffice of Clinical Research, Division of Allergy, Immunology and Transplantation, National Institutes of Health, Bethesda, Md

^cALPS Unit, National Institutes of Health, Bethesda, Md

^dMedical Virology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md

^eClinical Services Program, NCI-Frederick, Frederick, Md

^fClinical Monitoring Research Program, SAIC-Frederick, Inc, NCI-Frederick, Frederick, Md

To the Editor:

The autoimmune lymphoproliferative syndrome (ALPS) is characterized by chronic lymphadenopathy, splenomegaly, autoimmune cytopenias, and expansion of T cell receptor (TCR) $\alpha\beta^+ CD3^+ CD4^- CD8^-$ ($\alpha\beta$ -double-negative [DNT]) cells (see this article's Table E1 in the Online Repository at www.jacionline.org). Approximately two thirds of the patients with ALPS symptoms are genetically characterized, and most have germline (ALPS Ia) or somatic (ALPS Ia-s) *TNFRSF6* (*FAS*) mutations. A small number of patients have defects in genes encoding Fas ligand (ALPS Ib), caspase-10 (ALPS II), or neuroblastoma-RAS (NRAS) viral oncogene homolog (ALPS IV). In addition, a large group of patients with ALPS findings remain genetically uncharacterized (ALPS III), and yet another has an undefined ALPS-like syndrome (ALPS-phenotype; Table I).^{1,2} Given the clinical similarities among all these groups, we sought to develop a biomarkers-based algorithm to predict the presence or absence of *FAS* mutations in this setting.

To this end, we investigated 26 parameters including immunophenotyping, eosinophil and monocyte counts, serum or plasma vitamin B12 (B12), soluble FAS ligand (sFASL), immunoglobulins, and levels of 14 cytokines in 562 subjects classified into 6 categories (Tables I and E1). The number of measurements, medians, and first and third quartiles are presented in this article's Tables E2 and E3 in the Online Repository at www.jacionline.org.

Disclosure of potential conflict of interest: J. B. Oliveira is an employee of the National Institutes of Health. I. Caminha is a post-doctoral student at the National Institutes of Health Intramural Research Program. T. A. Fleisher is an employee of the National Institutes of Health and was President (July 2008 to June 2009) of the Robert A. Good Immunology Society. K. C. Dowdell is an employee of LCID/NIAID/NIH. The rest of the authors have declared that they have no conflict of interest.

A full description of the Methods can be found in the Online Repository at www.jacionline.org.

Elevated $\alpha\beta$ -DNT cells are a hallmark of ALPS, but their utility for predicting *FAS* mutations had not been previously evaluated.³ Patients with ALPS Ia and Ia-s had a high percentage of $\alpha\beta$ -DNT cells, with median values 5.1% and 7.7%, respectively, compared with 0.5% for control mutation-negative relatives (MNRs; $P < .0001$; Fig 1, A; Table E2). The $\alpha\beta$ -DNT level was predictive of *FAS* mutations, with values $>4\%$ found in 60% (90/152) of patients with type Ia and in the majority of patients with type Ia-s (7/9), but in only 13% (11/85) of patients with ALPS type III and ALPS-phenotype (Fig 1, A). This value was associated with a positive likelihood ratio (LR) of 5.0 and a posttest probability of 89.3% for harboring *FAS* mutations. Conversely, the presence of $\alpha\beta$ -DNT cells in the 1% to 2% range decreased the posttest probability to 25%, with a LR of 0.19 (Fig 2, B and C; see this article's Table E4 in the Online Repository at www.jacionline.org).

In line with previous reports, patients with ALPS, regardless of mutation status, had $<16\%$ of circulating B cells expressing the memory marker CD27 (Fig 1, B)⁴. Finding memory B cells $>16\%$ made the diagnosis of ALPS very unlikely (LR = 0.17). Other described abnormalities including increased CD3⁺HLA-DR⁺ to CD3⁺CD25⁺ ratio and high number of B cells had no additional diagnostic utility.⁴

We also evaluated serum B12 levels in patients with ALPS and found very elevated median levels in ALPS Ia and Ia-s (2259 ng/L; 1653 ng/L) compared with control MNRs (474 ng/L; $P < .0001$) and healthy mutation-positive relatives (570 ng/L; $P < .0001$). A modest but statistically significant increase was also noted in ALPS III and ALPS-phenotype, with medians of 759 ng/L and 943 ng/L, respectively (Fig 1, C). Levels above 1500 ng/L were observed in only 15% (4/28) of the patients with ALPS type III and ALPS-phenotype, contrasting with 63% (72/114) of patients with ALPS Ia. The LR for a *FAS* mutation with B12 levels >1500 ng/L was 4.0, with a posttest probability of 87%. In contrast, having B12 levels <1000 ng/L diminished the posttest probability to 35% (Fig 2, B and C; Table E4).

Analysis of plasma cytokines revealed 2 additional biomarkers for ALPS: IL-18 and TNF- α . Median plasma IL-18 levels were elevated in patients with ALPS Ia and Ia-s compared with control MNRs (1041 pg/mL, 1526 pg/mL, and 208 pg/mL, respectively; $P < .0001$). Patients with ALPS III and ALPS-phenotype had median values of 521 pg/mL and 702 pg/mL, respectively ($P < .001$ compared with MNRs; Fig 1, D). Furthermore, IL-18 <500 pg/mL was rarely seen in patients with ALPS and *FAS* mutations (7/56), with an associated negative LR of 0.19. TNF- α levels were higher in all ALPS groups with median values of 5 pg/mL for ALPS Ia ($P < .0001$), 9 pg/mL for ALPS Ia-s ($P < .05$), 8 pg/mL for ALPS III ($P < .0001$), and 7 pg/mL for ALPS-phenotype ($P < .0001$) compared with 1.3 pg/mL for MNRs (Fig 1, E).

As previously reported, IL-10 was markedly elevated in ALPS Ia and Ia-s compared with MNRs ($P < .0001$) and patients with ALPS III and ALPS-phenotype ($P < .0001$)^{5,6} (Fig 1, F). Sixty percent (83/139) of the patients with ALPS Ia and all patients with ALPS Ia-s exhibited values >40 pg/mL, contrasting with 26% (10/38) of patients with ALPS III and ALPS-phenotype. For levels of IL-10 >40 ng/mL, the positive LR was 3.8, with a posttest probability of 85% for having a *FAS* mutation. Notably, only 20% (29/141) of patients with ALPS Ia and no patients with ALPS Ia-s had IL-10 values <20 pg/mL, giving a negative LR of 0.31 and a posttest probability of 33% for *FAS* mutations (Fig 2, B and C; Table E4).

A recent report documented high levels of sFASL in patients with ALPS.⁷ We expanded these findings analyzing more than 200 patients and controls. Ninety-seven percent of patients with ALPS Ia (136/140) and all patients with ALPS Ia-s had plasma sFASL >200

pg/mL, with median values of 1114 pg/mL and 1329 pg/mL, respectively, compared with control MNR levels of 104 pg/mL ($P < .0001$ for both groups). Only modest elevations of sFASL were seen in patients with ALPS III and ALPS-phenotype, as well as healthy mutation-positive relatives, with median values of 208 pg/mL, 174 pg/mL, and 207 pg/mL, respectively (Fig 2, A). These findings make sFASL the most sensitive biomarker to rule out a *FAS* mutation, with values < 200 pg/mL associated with a negative LR of 0.05 and a posttest probability of 7.7% (Fig 2, C; Table E4). Soluble FASL also showed a strong positive correlation with IL-10 ($r = 0.8$; $P < .0001$) and a moderate correlation with $\alpha\beta$ -DNT cells ($r = 0.6$; $P < .0001$) and B12 levels ($r = 0.69$; $P < .0001$; see this article's Fig E1, A, in the Online Repository at www.jacionline.org). The area under the ROC curve for sFASL, $\alpha\beta$ -DNT cells, B12, and IL-10 levels were calculated to evaluate how well they discriminate patients with a *FAS* mutation from those without (Fig E1, B). The area under the curve for sFASL was 0.9 (defines an excellent test) and for $\alpha\beta$ -DNT cells was 0.81. B12 and IL-10 exhibited areas significantly less than sFASL ($P < .05$), with values of 0.76 and 0.77.

We next evaluated whether combinations of $\alpha\beta$ -DNT cells, B12, IL-10, IL-18, and sFASL would have increased power to predict or exclude *FAS* mutations in patients suspected of ALPS (Fig 2, B; Table E4). The combination of $\alpha\beta$ -DNT cells $> 4\%$ with B12 > 1500 ng/L or IL-10 > 40 pg/mL or IL-18 > 500 ng/mL or sFASL > 300 pg/mL was associated with $> 95\%$ probability of having a *FAS* mutation. Conversely, having $\alpha\beta$ -DNT cells $< 2\%$ in combination with IL-10 < 20 pg/mL or B12 < 1000 ng/L or IL-18 < 500 ng/mL decreased the probability of a *FAS* mutation to less than 10% (Fig 2, C; Table E4). Finally, finding $\alpha\beta$ -DNT cells $< 2\%$ and sFASL < 200 pg/mL resulted in $< 2\%$ probability for a *FAS* mutation.

In conclusion, the biomarkers described should aid in the selection of patients with findings of ALPS for further diagnostic workup. In addition, the presence of a combination of markers strongly suggestive of a *FAS* mutation in the setting of a negative genetic test should prompt a search for somatic mutations in sorted $\alpha\beta$ -DNT cells.

METHODS

Subjects

Five hundred sixty-two subjects studied at the National Institutes of Health under an Institutional Review Board–approved protocol were included in this study. All patients presented with lymphadenopathy and/or splenomegaly and $\alpha\beta$ -DNT cells above 1% of the total lymphocytes, typically associated with autoimmune cytopenias.

Biomarkers

Immunophenotyping, mutation analysis, and apoptosis assays were performed as previously described.^{E1–E3} Vitamin B12 levels, immunoglobulin measurements, and monocyte and eosinophil counts were obtained by reviewing medical and laboratory records of all participants. For patients with repeated measurements, the first available result was used, regardless of the clinical status or ongoing therapy.

The quantification of plasma ILs was performed by ELISA following the manufacturer's instructions. sFASL, TNF- α , IL-2, IL-7, IL-13, and IL-15 kits were from R&D Systems (Minneapolis, Minn); IL-18 was from MBL Co, Ltd (Naku-ku Nagoya, Japan); IL-10, IL-1b, IL-4, IL-5, IL-6, and IFN- γ kits were from Endogen; IL-12 was from Biosource International (Camarillo, Calif); and IL-23 from Bender Medsystems (Vienna, Austria). The measurements were performed on frozen plasma samples, and for patients with more than 1 sample available, the first collected sample was used for testing. One technical aspect worth noting is that IL-18 levels are spuriously increased in blood samples shipped overnight,

especially in the warm summer months, so that only fresh samples (<8h post drawing time) should be used for analysis.

Statistical analysis

Statistical analysis was performed by using Prism (Graphpad Software, San Diego, Calif), JMP-7 (SAS, Cary, NC) and the statistical and graphics language R version 2.9.0 (<http://www.R-project.org>). The Wilcoxon-Mann-Whitney test was used to compare groups. Sensitivity and specificity of each biomarker to detect ALPS and *FAS* mutations were obtained, and LR⁺ = sensitivity/100 – specificity; LR[–] = 100 – sensitivity/specificity), odds ratios (odds posttest = odds pretest × LR), and probabilities ([odd/1 + odd] × 100) were calculated. Pretest odds and probability for having a *FAS* mutation were obtained by calculating the prevalence of *FAS* mutations on our whole cohort of patients and were found to be 1.7 and 63%, respectively. When associating more than 1 biomarker, the posttest odds were calculated by multiplying the pretest odds by the combination of LR_s (odds posttest = odds pretest × LR₁ × LR₂ × ... × LR_n). Receiver operating characteristic curves were used to evaluate the best levels of vitamin B12, IL-10, sFASL, and αβ-DNTable to differentiate *FAS* mutants from no mutants and to evaluate the accuracy of the biomarkers.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Supported in part by the Intramural NIH Research Program of the NIH Clinical Center and the National Institute of Allergy and Infectious Disease. This project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.

REFERENCES

1. Bidere N, Su HC, Lenardo MJ. Genetic disorders of programmed cell death in the immune system. *Annu Rev Immunol*. 2006; 24:321–352. [PubMed: 16551252]
2. Oliveira JB, Bidere N, Niemela JE, Zheng L, Sakai K, Nix CP, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. *Proc Natl Acad Sci U S A*. 2007; 104:8953–8958. [PubMed: 17517660]
3. Sneller MC, Straus SE, Jaffe ES, Jaffe JS, Fleisher TA, Stetler-Stevenson M, et al. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. *J Clin Invest*. 1992; 90:334–341. [PubMed: 1386609]
4. Bleesing JJ, Brown MR, Straus SE, Dale JK, Siegel RM, Johnson M, et al. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. *Blood*. 2001; 98:2466–2473. [PubMed: 11588044]
5. Lopatin U, Yao X, Williams RK, Bleesing JJ, Dale JK, Wong D, et al. Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. *Blood*. 2001; 97:3161–3170. [PubMed: 11342444]
6. Fuss IJ, Strober W, Dale JK, Fritz S, Pearlstein GR, Puck JM, et al. Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humoral autoimmunity. *J Immunol*. 1997; 158:1912–1918. [PubMed: 9029133]
7. Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, Neven B, Schaffner C, Ducrot N, et al. FAS-L, IL-10, and double-negative CD4[–] CD8[–] TCR alpha/beta⁺ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. *Blood*. 2009; 113:3027–3030. [PubMed: 19176318]

REFERENCES

- E1. Jackson CE, Fischer RE, Hsu AP, Anderson SM, Choi Y, Wang J, et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. *Am J Hum Genet.* 1999; 64:1002–1014. [PubMed: 10090885]
- E2. Oliveira JB, Bidere N, Niemela JE, Zheng L, Sakai K, Nix CP, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. *Proc Natl Acad Sci U S A.* 2007; 104:8953–8958. [PubMed: 17517660]
- E3. Bleesing JJ, Brown MR, Straus SE, Dale JK, Siegel RM, Johnson M, et al. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. *Blood.* 2001; 98:2466–2473. [PubMed: 11588044]

FIG 1.

Biomarkers in patients with ALPS and control groups. *Dashed lines* represent cut-off values used to calculate likelihood ratios. *Bars* denote median values. *P* values for the differences between groups were obtained by Mann-Whitney test and are shown above each graph ($***P < .0001$; $**P < .001$; $*P < .05$; *NS*, no significant difference). *HMPR*, Healthy mutation-positive relative; *MNR*, mutation negative relative.

FIG 2.

sFASL levels and combinations of biomarkers accurately predict *FAS* mutations. **A**, Scatter plot showing sFASL levels. Increasing **(B)** and decreasing **(C)** probabilities for having a *FAS* mutation according to the percentage of $\alpha\beta$ -DNT cells, levels of vitamin B12, IL-10, IL-18, sFASL, and results of FAS-induced apoptosis assay. Bars denote median values. *P* values for the differences between groups were obtained by Mann-Whitney test and are shown above each graph (****P* < .0001; ***P* < .001; **P* < .05; NS, no significant difference). *HMPR*, Healthy mutation-positive relative.

TABLE I

Description of patients with ALPS and control groups included in the study

Classification	Description	No. of subjects
ALPS Ia	Patients with ALPS and germline <i>FAS</i> mutations	162
ALPS Ia-s	Patients with ALPS and somatic <i>FAS</i> mutations	9
Healthy mutation-positive relatives	Healthy relatives of patients with ALPS Ia who carry a <i>FAS</i> mutation	115
Mutation negative relatives	Healthy relatives of patients with ALPS Ia who do not carry a <i>FAS</i> mutation	179
ALPS III	Patients who fulfill criteria for ALPS but have no causative mutation identified	52
ALPS-phenotype	Patients with autoimmune cytopenias, lymphadenopathy/splenomegaly, and $\alpha\beta$ -DNT cells > 1%, without genetic abnormalities or lymphocyte defective apoptosis	40